Metraipolis › archive › dc_d37841fea840
Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort — Europe PMC PMID:42126632
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42126632
- DOI
- 10.1007/s00415-[numero omesso]-0
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T17:45:13.398Z
- SHA-256 of the archived text
49008ea9c67574eb037def0d6e29b80025ed38f9ae62ad8cadf72c210485b35a- Stable URL of this page
https://metraipolis.com/documento/dc_d37841fea840
How to cite
Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort — Europe PMC PMID:42126632 — Europe PMC (en), https://europepmc.org/article/MED/42126632 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d37841fea840 (Metraipolis archive dc_d37841fea840, sha256 49008ea9c67574eb037def0d6e29b80025ed38f9ae62ad8cadf72c210485b35a)
BibTeX
@misc{dcd37841fea840,
title = {Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort — Europe PMC PMID:42126632},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42126632},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d37841fea840; sha256 49008ea9c67574eb037def0d6e29b80025ed38f9ae62ad8cadf72c210485b35a},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42126632. Agents can read the archived copy with the MCP tool read_document.